Call Us : 1.224.938.9523
Ranjan Duara, MD

Welcome Notes: Introduction to the MCI Symposium 2016

David A. Bennett, MD

Keynote Lecture: Genes, AD Pathology, Cerebrovascular Disease, and AD Dementia

Charles Duyckaerts, MD, PhD

Aging, Alzheimer Disease and Vascular Pathology: Which are the Determinants of Cognitive Impairment?

David Morgan, PhD

Innate Immune Activation in Neurodegenerative Disease: Differential Effects on Amyloid and Tau Pathology

Sudha Seshadri, MD

Genetic Pathways Linking Neuroinflammation, Vascular Disease and Neurodegeneration

Charles S. DeCarli, MD

Impact of Vascular Risk Factors on Cognition Independent of Amyloid and MRI Measures of AD and CVD

Colm Cunningham, PhD

Systemic Inflammation Triggers Acute Delirium, Brain Injury and Contributes to Accelerated Neurodegeneration

Oscar Lopez, MD

Markers of Inflammation and Immune Activation, Small Vessel Disease, Amyloid Deposition and Progression to Dementia in Non-Demented Individuals

Miia Kivipelto, MD, PhD

Lifestyle Intervention To Prevent Cognitive Impairment

Panel Discussion and Q&A

Moderator: Vladimir Hachinski, CM, MD, DSc, FRCP, University of Western Ontario

Ingmar Skoog, PhD

The Epidemiological Relevance of Subjective Cognitive Decline

Rebecca Amariglio, PhD

Subjective Cognitive Concerns and Biomarker Evidence of Preclinical Alzheimer’s Disease

Beth Snitz, PhD

Subjective Cognitive Impairment, Neuroticism and Brain Amyloid Load

Andrew J. Saykin, PsyD

Family History, Subjective Memory Complaints and Brain Amyloid Load in the ADNI Study

Frederick Schmitt, PhD

Neuropathology Among Cognitively Normal Brain Donors, With & Without Subjective Memory Complaints

Marwan Sabbagh, MD

APOE e4, Subjective Memory Symptoms and Cognitive Decline

Panel Discussion and Q&A

Moderator: Ronald C. Petersen, MD, PhD, Mayo Clinic

Philip Scheltens, MD, PhD

Keynote Lecture: The Prevalence of Amyloid Positivity by Age, APOE Genotype and Cognitive Status – Implications for the Diagnosis of Alzheimer’s Disease

Gil Rabinovici, MD

Biomarker Patterns in Subtypes of Alzheimer’s Disease – Implications for Pathophysiology and Diagnosis

Reisa A. Sperling, MD, MMSc

Detection of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

Bruno Dubois, MD

The Added Value of the International Working Group – 2 Diagnostic Criteria for Alzheimer’s Disease

Julie Schneider, MD

Diagnostic Complexities in Current Clinical and Morphological Criteria for Alzheimer’s Disease

Howard Chertkow, MD

A Canadian Consensus: Defining MCI for Clinical and Research Purposes

John C. Morris, MD

Harmonized Clinical Diagnostic Criteria for the Incipient Symptomatic Stages of Alzheimer’s Disease

Panel Discussion and Q&A

Moderator: David Knopman, MD, Mayo Clinic Rochester

Ranjan Duara, MD and Steven T. DeKosky, MD

Introductory Notes Public Educational Forum

Vladimir Hachinski, CM, MD, DSc, FRCP

Alzheimer’s Disease: Between the Inevitable and the Modifiable

Ingmar Skoog, PhD

What are Subjective Memory Complaints and What is their Significance?

Frederick Schmitt, PhD

Why is an Early Diagnosis of Alzheimer’s Important and How Do We Achieve It?

Mary Ganguli, MD, MPH

The Link Between Depression, Anxiety and Alzheimer’s Disease

David A. Bennett, MD

What have we Learned from Brain Autopsies of Persons with and without Dementia

Amanda Smith, MD

The Importance of Participating in Clinical Trials in Alzheimer’s Disease

Panel Discussion and Q&A

Moderator: Steven T. DeKosky, MD